Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068438 | 0.76 | LMNA (0.37) | IDO1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL24848367 | 0.73 | MAOA (0.36) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL29669644 | 0.67 | — | — | |
| SCHEMBL7078672 | 0.62 | TYR (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL21110938 | 0.62 | TYR (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL10383431 | 0.61 | MAPT (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL13896928 | 0.61 | MAPT (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL29363125 | 0.60 | MAPT (0.33) | LMNA | |
| SCHEMBL30546551 | 0.59 | HPGD (0.31) | LMNA | |
| SCHEMBL25383684 | 0.58 | HPSE (0.45) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119331136-A | Components of olefin polymerization catalyst, olefin polymerization catalyst and application thereof | 中国石油天然气股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-119331136-A | Components of olefin polymerization catalyst, olefin polymerization catalyst and application thereof | 中国石油天然气股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-3116851-B1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INST FOR BIOLOGICAL STUDI (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11440889-B2 | Analogs of fexaramine and methods of making and using | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-09-13 | — | — | US | disclosed |
| US-20210147365-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-05-20 | — | — | US | disclosed |
| US-10815203-B2 | Analogs of fexaramine and methods of making and using | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200123113-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-04-23 | — | — | US | disclosed |
| US-10450277-B2 | Analogs of fexaramine and methods of making and using | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-10-22 | — | — | US | disclosed |
| US-10301268-B2 | Analogs of fexaramine and methods of making and using | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190084939-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-03-21 | — | — | US | disclosed |
| EP-3267991-A1 | TREATING LATENT AUTOIMMUNE DIABETES OF ADULTS WITH FARNESOID X RECEPTOR AGONISTS TO ACTIVATE INTESTINAL RECEPTORS | Salk Institute for Biological Studies (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2017078927-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| EP-3116851-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | Salk Institute for Biological Studies (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2016149111-A1 | TREATING LATENT AUTOIMMUNE DIABETES OF ADULTS WITH FARNESOID X RECEPTOR AGONISTS TO ACTIVATE INTESTINAL RECEPTORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-09-22 | — | — | WO | disclosed |
| WO-2015138969-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20060189682-A1 | Water soluble prodrugs of COX-2 inhibitors | MERCK & CO., INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | IDO1 251/4885LMNA 2161/4885CYP1A2 2597/4885 |
| US-11440889-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | IDO1 166/4885LMNA 4205/4885CYP1A2 183/4885 |
| US-20210147365-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | IDO1 166/4885LMNA 4205/4885CYP1A2 183/4885 |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | IDO1 166/4885LMNA 4205/4885CYP1A2 183/4885 |
| US-10815203-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | IDO1 166/4885LMNA 4205/4885CYP1A2 183/4885 |
| US-10450277-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | IDO1 166/4885LMNA 4205/4885CYP1A2 183/4885 |
| US-20190084939-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | IDO1 166/4885LMNA 4205/4885CYP1A2 183/4885 |
| US-10301268-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | IDO1 166/4885LMNA 4205/4885CYP1A2 183/4885 |
| US-20200123113-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | IDO1 166/4885LMNA 4205/4885CYP1A2 183/4885 |
| US-20060189682-A1 | Water soluble prodrugs of COX-2 inhibitors | PTGS2, PTGES2, PTGIS | IDO1 463/4885LMNA 3552/4885CYP1A2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.